3Itoh A, Nitta A, Nadai M, et al.Dysfunction of cholinergic and dopaminergic neuronal systems in beta-amyloid protein--infused rats[J]. J Neurochem,1996;66(3):1113-7.
4Kato M, Saito H, Abe K. Nanomolar amyloid beta protein-induced inhibition of cellular redox activity in cultured astrocytes[J]. J Neurochem,1997; 68(5): 1889-95.
5Muller WE, Stoll L, Schubert T, et al.Central cholinergic functioning and aging[J]. Acta Psychiatr Scand SuPPl,1991;366:34-9.
6Bonkale WL, Fastbom J, Wiehager B, et al.Impaired G-protein-stimulated adenylyl cyclase activity in Alzheimer's disease brain is not accompanied by reduced cyclic-AMP-dependent protein kinase Aactivity[J]. Brain Res,1996;737(1-2):155-61.
7Rodriguez-Puertas R, Pascual J, Vilaro T, et al.Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease[J]. Synapse,1997;26(4):341-50.
8Pauly JR. Nicotinic cholinergic receptor deficits in Alzheimer's disease: Where's the smoke[J] J Alzheimers Dis,1999;1(4,5):221-30.
9Flynn DD, Ferrari-DiLeo G, Levey AI, et al.Differential alterations in muscarinic receptor subtypes in Alzheimer's disease:Implications for cholinergic-based therapies[J]. Life Sci. 1995;56(11-12):869-76.
10Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain:Changes with aging and dementia[J].J Neurosci Res,1992;31(1):103-10.
二级参考文献8
1Feldman H,Gauthier S,Hecker J,et al. A 24-week, randomized,double-blind study of donepezil in moderate to severe Alzheimer's disease . Neurology, 2001,57 (4) : 613-620.
2R oe sler M,Anand R,Cicin—Sain A,et a1.Efficacy and safety of rivastigmine in patients with Alzheimer’s disease:International randomized controlled trial[J].BMJ,1999；318(3):633—640.
3Winblad B,Engedal K,Soininen H,et a1.A 1-year,randomized,placebo—controlled study of donepezil in patients with mild to moderate AD.Neurology.2001；57(3):489-495.
4Krall JW,Sramek JJ,Cutler NR. Cholinesterase inhibition : A therapeutie strategy for Alzheimer's disease. Ann Pharmacother,1999;33(4):411-417.
5Davis KL,Mohs RC,Marin D,et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease . JAMA, 1999;281(11) ,1401-1406.
6Gilmor ML,Erickson JD,Varoqui H,et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vescular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease [J]. J Comp Neurol,1999;411(3) : 693-704.
6Riker WK,Roberts JRJ,Standaert FG,et al. The motor nerve terminal as the primary focus for drug-induced facilitation of neuromuscular transmission [J]. J Pharmacol Exp Ther,1957,121:286.
7Laduron PM. Presynaptic heteroreceptors in regulation of neuronal transmission [J]. Biochem Pharmacol, 1985, 34(4):467.
8Wu LG, Saggau P. Presnaptic inhibition of elicited neurotransmitter release [J]. Trends Neurosci, 1997,20(5):204.
9Langer SZ, Scatton B, Schoemaker H, et al. Presynaptic autoreceptors and heteroreceptors are both alive and kicking[J]. Trends Pharmacol Sci, 1998, 19(4):127.
10MacDermott AB, Role LW, Siegelbaum SA. Presynaptic ionotropic receptors and the control of transmitter release [J]. Annu Rev Neurosci, 1999, 22:443.
